B+
Bull case
15%
Probability
Target price
$1.05
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
BBLG
Bone BiologicsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$0.58
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+65.3
Score
AI commentary
BBLG remains a low-conviction monitoring name. Primary filings and the July company update provide useful liquidity and program-status evidence, but the post-earnings evidence set lacks consensus surprise data, analyst revisions, and verified market-reaction attribution. The August 14 anchor price was $0.655, while the deterministic prior remains negative with expected returns of -1.9% over 5 days, -5.4% over 20 days, and -8.7% over 60 days. Social and recent-news coverage are absent, so confidence should remain constrained.
RankAlpha Sentiment Codex - 2026-08-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-14eventPost-earnings liquidity checkpointMedium impact
The latest 10-Q reported $4.0 million of cash at June 30, 2026, approximately $2.7 million of net proceeds from the July placement, a $1.5 million six-month net loss, and $1.3 million of operating cash use. The filing indicates available cash is expected to fund operations into Q2 2027, but also notes substantial doubt about continuing as a going concern [#SEC-10Q-2026-08-14].
2026-10-01catalystFinancing runway versus dilution overhangHigh impact
The July private placement generated approximately $3.0 million gross proceeds and included warrants for up to approximately $6.0 million of additional gross proceeds if exercised. The financing extends the stated operating runway through Q2 2027, but potential warrant and future equity issuance remain supply and dilution risks [#8-K-2026-07-23] [#SEC-10Q-2026-08-14].
2026-12-31catalystNB1 enrollment completion and clinical executionHigh impact
Bone Biologics said it expects to complete enrollment in its first-in-human NB1 pilot study by year-end 2026. NB1 combines rhNELL-1 with demineralized bone matrix for spinal fusion; the checked source does not provide current enrollment, efficacy, or safety results, so this remains a binary and execution-dependent upside hook [#8-K-2026-07-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology